Jose Rubio-Briones

Valencia, VC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 140 publications

From Target Plausibility to Analytical Recovery: Digital PCR-Based Uromonitor and the Platform Question in Urinary Tumor DNA Surveillance.

From Target Plausibility to Analytical Recovery: Digital PCR-Based Uromonitor and the Platform Question in Urinary Tumor DNA Surveillance.

Journal: Clinical genitourinary cancer

Published: June 15, 2026

Response to: "Caution in interpreting the diagnostic superiority of digital Uromonitor in NMIBC surveillance".

Response to: "Caution in interpreting the diagnostic superiority of digital Uromonitor in NMIBC surveillance".

Journal: BJU international

Published: June 01, 2026

Digital Uromonitor® outperforms quantitative polymerase chain reaction Uromonitor and cytology for non-muscle-invasive bladder cancer surveillance: results from the 'External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the Club Urológico Español de Tratamiento Oncológico Group' (EVALUATION-CUETO) study.

Digital Uromonitor® outperforms quantitative polymerase chain reaction Uromonitor and cytology for non-muscle-invasive bladder cancer surveillance: results from the 'External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the Club Urológico Español de Tratamiento Oncológico Group' (EVALUATION-CUETO) study.

Journal: BJU international

Published: April 06, 2026

Improving long-term monitoring in NMIBC: Digital Uromonitor® (dUM) as a complementary tool to cystoscopy for two-year recurrence risk stratification.

Improving long-term monitoring in NMIBC: Digital Uromonitor® (dUM) as a complementary tool to cystoscopy for two-year recurrence risk stratification.

Journal: Actas urologicas espanolas

Published: February 02, 2026

Improving Long-Term Monitoring in NMIBC: Digital Uromonitor® (dUM) as a Complementary Tool to Cystoscopy for Two-Year Recurrence Risk Stratification.

Improving Long-Term Monitoring in NMIBC: Digital Uromonitor® (dUM) as a Complementary Tool to Cystoscopy for Two-Year Recurrence Risk Stratification.

Journal: Actas urologicas espanolas

Published: February 02, 2026

Epidemiology, Comorbidities and Associated Treatments, Therapeutic Management, and Clinical Outcomes in Patients with Prostate Cancer in Spain (SRealProstate): A Real-World Cohort Study.

Epidemiology, Comorbidities and Associated Treatments, Therapeutic Management, and Clinical Outcomes in Patients with Prostate Cancer in Spain (SRealProstate): A Real-World Cohort Study.

Journal: Cancers

Published: December 30, 2025

Diagnostic Performance and Clinical Utility of the Uromonitor® Molecular Urine Assay for Urothelial Carcinoma of the Bladder: A Systematic Review and Diagnostic Accuracy Meta-Analysis.

Diagnostic Performance and Clinical Utility of the Uromonitor® Molecular Urine Assay for Urothelial Carcinoma of the Bladder: A Systematic Review and Diagnostic Accuracy Meta-Analysis.

Journal: Diagnostics (Basel, Switzerland)

Published: December 19, 2025

Response to: 'Expanding the evidence base for Uromonitor®: updated pooled performance across eight cohorts'.

Response to: 'Expanding the evidence base for Uromonitor®: updated pooled performance across eight cohorts'.

Journal: BJU international

Published: December 12, 2025

External validation of the Uromonitor®-version 2 urine test as a biomarker for optimisation of non-muscle-invasive bladder cancer management.

External validation of the Uromonitor®-version 2 urine test as a biomarker for optimisation of non-muscle-invasive bladder cancer management.

Journal: BJU international

Published: October 01, 2025

Accuracy of large language models in interpreting urological clinical guidelines: a comparative study with expert evaluation.

Accuracy of large language models in interpreting urological clinical guidelines: a comparative study with expert evaluation.

Journal: Therapeutic advances in urology

Published: August 26, 2025

External validation of the heidenreich criteria for patients with post-chemotherapy residual masses of non-seminomatous germ cell tumor.

External validation of the heidenreich criteria for patients with post-chemotherapy residual masses of non-seminomatous germ cell tumor.

Journal: The Canadian journal of urology

Published: July 09, 2025

The key to humanitarian urology: do not import the surgeon, create trained local surgical teams.

The key to humanitarian urology: do not import the surgeon, create trained local surgical teams.

Journal: Nature reviews. Urology

Published: February 10, 2025

Showing 1-12 of 140

Last Updated: 09/26/2026